Therapies for allergic, inflammatory conditions

Upstream Bio is focused on developing innovative treatments for inflammatory diseases, with a particular emphasis on their lead product, verekitug. This clinical-stage monoclonal antibody is designed to target an upstream driver of the inflammatory response, which positions it uniquely in the therapeutic landscape. By addressing the root causes of inflammation, Upstream Bio aims to enhance treatment options for patients suffering from severe inflammatory conditions, thereby improving their overall health and quality of life.

The company is driven by a team of experienced professionals dedicated to advancing the science behind verekitug's mechanism of action. Their commitment to addressing unmet patient needs in the realm of inflammatory diseases underscores their mission to empower both employees and patients alike. Through their innovative approach, Upstream Bio seeks to make significant strides in the treatment of inflammatory diseases, ultimately aiming to provide better health outcomes for millions of individuals affected by these conditions.

United States

At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. 

Upstream Bio

Company Details